ARCHIVES

In Brief: James Downing named CEO of St. Jude

This article is from The Cancer Letter archive.

Vol. 40 No. 26 | June 27, 2014

Download PDF Visit The Full Archive

Related Articles

Duke wins Avon-NCI funding.

October 31, 2003

Anti-Nausea Drug Successful In Phase III Trial in Highly Emetogenic Chemotherapy

May 30, 2014

Komen, ACS Support Payment Off-Protocol; Dilemma for Advocates

April 16, 1999

In Brief: New Greg For Surgery Research Approved; Only 30 Bioassay Program Reports Still In Backlog

April 21, 1978

HHS Carcinogen Guidelines Draft

June 13, 1980

Cancer Telethon Attracts Small Audience, Generates Expectations-And Questions.

September 12, 2008